
Cellectis is a French biotech company that specializes in gene editing and immunotherapy. Founded in 2007, the company has made significant strides in developing innovative treatments for various diseases.
Cellectis' business operations are centered around its proprietary TALEN gene editing technology, which allows for precise editing of the human genome. This technology has been used to develop treatments for blood-related disorders, such as sickle cell disease and beta-thalassemia.
The company has also made advancements in CAR-T cell therapy, a type of immunotherapy that uses genetically modified T cells to fight cancer.
Check this out: Lukens Steel Company
Business and Operations
Cellectis, a French biotechnology company, has made significant strides in the field of gene editing. They have developed a unique approach to gene editing using TALENs and CRISPR/Cas9.
Cellectis' business model is built around licensing their TALEN technology to pharmaceutical companies and research institutions. This approach allows them to generate revenue without having to develop their own products.
Their focus on licensing rather than developing their own products has helped them to quickly expand their reach and partnerships.
You might enjoy: Abengoa
Full Time Employees

Full-time employees are a crucial part of any business, making up the core team that drives operations forward.
According to our research, the average number of full-time employees in a small business is around 10-20 people. This size team allows for efficient communication and collaboration, making it easier to achieve business goals.
Having a diverse team with a mix of skills and experience is essential for success. In fact, a study found that teams with a diverse range of skills are 15% more productive than those with a limited range of skills.
Full-time employees are also responsible for the day-to-day operations of the business, including managing customer relationships and handling administrative tasks. This can help reduce the workload of the business owner and allow them to focus on strategic decision-making.
In some cases, full-time employees may also be responsible for managing other employees, such as part-time or temporary staff. This can be a challenging but rewarding role, requiring strong leadership and communication skills.
Business owners should consider the costs associated with hiring full-time employees, including salaries, benefits, and training expenses. These costs can add up quickly, so it's essential to have a solid business plan in place to ensure financial stability.
On a similar theme: Business & Decision
Details of Ucart

Cellectis' UCART products are allogeneic CAR T-cells developed using the company's gene-editing platform TALEN and proprietary PulseAgile electroporation technologies. This technology allows for precise and targeted modification of a gene.
The UCART products target selective tumour antigens and harness the immune system's ability to target cancer cells in the body. They are designed to be safe and compatible.
TALEN enables the engineering of safer and more compatible features into the product. PulseAgile electroporation technologies deliver mRNA or DNA into the cells using controlled electric fields.
The UCART products are easy to use and high-yielding, which should help combat the issue of high drug prices by lowering production costs.
Financials
Cellectis' financials paint a concerning picture. The company's profit margin is a staggering -93.00%, indicating that it's losing money on almost every sale.
The return on assets (ttm) is also negative, standing at -7.43%, suggesting that the company's assets are not generating enough revenue to cover expenses.
Additional reading: Orange France Company
In contrast, the return on equity (ttm) is a whopping -48.02%, showing that even the company's shareholders are not seeing a positive return on their investment.
Revenue, however, is a respectable $63.44 million, but it's not enough to offset the company's significant losses.
Here are some key financial metrics for Cellectis:
Cellectis' market capitalization is around $338.42 million, while its enterprise value is $237.04 million.
Investors and Funding
Cellectis has received funding over three rounds, with its first round taking place on March 25, 2014. This was a significant milestone for the company.
Cellectis's latest funding round was a Post IPO round on May 06, 2024, which raised $140M. This investment was led by Ridgeback Capital Management, Orbimed, VenBio, and Odyssee Venture.
The company has 11 institutional investors, including Ridgeback Capital Management, Orbimed, and VenBio. Astrazeneca was also an investor in the latest funding round.
Here is a summary of Cellectis's funding rounds:
Funding and Investors
Cellectis has a history of securing funding to support its growth. Its first funding round was on March 25, 2014.
The company has raised funding over three rounds, with its latest round being a Post IPO round on May 06, 2024 for $140M. This round was led by Ridgeback Capital Management, Orbimed, VenBio, and Odyssee Venture.
Cellectis has a total of 11 institutional investors, including Ridgeback Capital Management, Orbimed, and VenBio.
Here is a list of the company's funding rounds:
In its latest funding round, Astrazeneca was the sole investor.
Analyst Recommendations
Analyst Recommendations can be a game-changer for investors. Many analysts recommend diversifying your portfolio with a mix of low-risk and high-risk investments.
Investors should consider the advice of reputable analysts, such as those from top investment banks, who often provide detailed research reports on various stocks and industries. These reports can help investors make informed decisions.
Some analysts recommend investing in established companies with a strong track record of financial performance, such as those with a history of consistent revenue growth. Consistently profitable companies like this can provide a stable source of returns.
Others suggest exploring emerging industries and companies with innovative products or services, which can offer higher growth potential. However, this approach also comes with higher risks, so it's essential to carefully evaluate the potential rewards and risks.
Investors should also pay attention to analyst ratings, such as buy, hold, or sell recommendations, which can provide valuable insights into a company's prospects. For example, a buy rating from a reputable analyst can indicate a high level of confidence in a company's future performance.
Ultimately, investors should use analyst recommendations as just one tool in their decision-making process, combining it with their own research and risk tolerance to make informed investment choices.
Industry and Market
Cellectis is a key player in the development of UCART-based immunotherapies. The company operates a 14,000ft² manufacturing facility in Paris called Starting Material Realization for CAR-T products (SMART).
This facility is crucial for manufacturing and supplying starting materials for clinical trials and UCART products. The company has partnerships with several major players in the industry, including AstraZeneca, Allogene Therapeutics, Servier, Iovance Biotherapeutics, and Primera Therapeutics.
Suggestion: Juno Therapeutics
Sector
The sector is a crucial aspect of the industry and market.
The consumer goods sector is one of the largest sectors in the industry, accounting for a significant share of the market.
The consumer goods sector includes companies that produce and sell everyday products such as food, beverages, and household items.
In the consumer goods sector, companies like Procter & Gamble and Unilever dominate the market with their wide range of products.
The technology sector is another significant sector in the industry, with companies like Apple and Google leading the way.
The technology sector is driven by innovation and is constantly evolving, with new technologies and products emerging all the time.
The healthcare sector is also a major sector in the industry, with companies like Johnson & Johnson and Pfizer developing life-saving medicines and medical devices.
The healthcare sector is driven by the need to improve human health and well-being, and companies in this sector are constantly seeking new ways to innovate and improve their products.
Industry

Cellectis is a company involved in the development of UCART-based immunotherapies. They have a manufacturing facility in Paris that produces starting materials for clinical trials and UCART products.
The facility, named SMART, spans 14,000 square feet.
Cellectis partners with several companies, including AstraZeneca, Allogene Therapeutics, Servier, Iovance Biotherapeutics, and Primera Therapeutics, to develop, manufacture, and commercialize products.
A fresh viewpoint: Acorda Therapeutics
Competitors and Alternates
Cellectis has several competitors and alternates in the industry. Moderna, the number one ranked company, has a total funding of $2.78B and is a developer of mRNA-based therapeutics for a wide range of diseases.
Moderna is a public company based in Cambridge, United States, and has received funding from prominent investors such as BB Biotech and Gershon Capital. They have a Tracxn Score of 80/100.
BeiGene, the second ranked company, has a total funding of $172M and is a developer of targeted and immune-oncology drugs against cancer. They are a public company based in Cambridge, United States.
See what others are reading: Moderna
Here's a list of the top 5 competitors and alternates in the industry, ranked by their overall rank:
Cellectis's Tracxn Score is 45/100, indicating that it has a lower ranking compared to its competitors. However, Cellectis is still a developer of cancer immunotherapies based on gene-edited CAR T-cells, and has received funding from prominent investors such as Ridgeback Capital Management and Orbimed.
Technology and Treatment
Cellectis has developed a groundbreaking CAR-T cancer treatment that uses gene editing to disable the gene that causes donor immune cells to attack their host, preventing graft vs host disease.
The company's approach starts with T-cells taken from healthy donors, which are then modified using gene editing to target cancer cells.
Cellectis' UCART products are allogeneic CAR T-cells developed using the company's gene-editing platform TALEN and PulseAgile electroporation technologies, making them easy to use and high-yielding.
These products harness the immune system's ability to target cancer cells in the body, with the main UCART candidates in the company's portfolio including UCART19, UCART123, UCART22, and others.
Cellectis' UCART products have shown promise in treating various types of blood cancers, including blastic plasmacytoid dendritic cell neoplasm and acute myeloid leukemia.
Impact Facility Details

The IMPACT facility is an 82,000ft² state-of-the-art manufacturing plant.
Cellectis' IMPACT facility is dedicated to the development of UCART products and follows good manufacturing practices (GMP) guidelines according to the US FDA and European Medicines Agency (EMA).
This facility is designed to be flexible and adaptable as technology advances, thanks to the design by CRB Group, an engineering and construction services provider.
The IMPACT facility is equipped to support future regulatory approvals, ensuring Cellectis is well-prepared for any upcoming requirements.
Cellectis previously manufactured UCART for clinical trials and starting materials through contract manufacturing organisations MolMed and CellForCure.
Car-T Cancer Treatment
Cellectis has developed CAR T-cell treatments for blood cancer, using an allogeneic approach by taking T-cells from healthy donors and modifying them with gene editing to disable the gene that causes donor immune cells to attack their host.
The company's UCART products are designed to target selective tumour antigens and harness the immune system's ability to target cancer cells in the body.
Cellectis' approach to CAR-T therapy involves using the company's gene-editing platform TALEN and proprietary PulseAgile electroporation technologies to deliver mRNA or DNA into the cells using controlled electric fields.
The UCART products are easy to use and high-yielding, which could combat the issue of high drug prices by lowering production costs.
Cellectis' UCART candidates include UCART19, UCART123, UCART22, UCARTCS1, UCARTCLL1, ALLO-501, ALLO-715 and ALLO-819, all of which are in various stages of clinical trials for different types of blood cancer.
In 2017, UCART123 was in phase 1 trials for blastic plasmacytoid dendritic cell neoplasm (BPDCN) and acute myeloid leukaemia (AML), but the FDA suspended the trial due to a patient's death from cytokine release syndrome (CRS).
Marketing Commentary
Cellectis is a company that's making waves in the field of immunotherapy, particularly with its UCART-based treatments. They're also quite serious about manufacturing, having set up a 14,000ft² facility in Paris.
This facility, named SMART, is where they produce starting materials for clinical trials and UCART products. It's a big deal, and they're not doing it alone - they've partnered with some major players in the industry, including AstraZeneca and Allogene Therapeutics.
These partners are working together to develop, manufacture, and commercialize products, which is a testament to Cellectis's ability to collaborate and drive progress. They've also got agreements with Iovance Biotherapeutics and Primera Therapeutics, further expanding their reach.
A different take: United Therapeutics
Frequently Asked Questions
How many employees does Cellectis have?
As of December 31, 2024, Cellectis has a total of 222 employees, consisting of 216 full-time and 6 part-time staff members.
Where is Cellectis located?
Cellectis has headquarters in Paris, France, with additional locations in New York and Raleigh, North Carolina. Learn more about our global presence and innovative work in gene editing.
Featured Images: pexels.com
